Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 5/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | NQO2 | P16083 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | GLA | P06280 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | CASP7 | P55210 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | CFTR | P13569 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31546995 | 0.93 | GAA (0.53) | GAAABL1NQO2KDM4EALDH1A1 | |
| SCHEMBL3340065 | 0.93 | GAA (0.53) | GAAABL1NQO2KDM4EALDH1A1 | |
| SCHEMBL3529471 | 0.86 | ABL1 (0.56) | GAAABL1NQO2KDM4EALDH1A1 | |
| SCHEMBL9793695 | 0.85 | GAA (0.59) | GAAABL1NQO2KDM4EALDH1A1 | |
| SCHEMBL23774898 | 0.84 | GAA (0.54) | GAAABL1NQO2KDM4EALDH1A1 | |
| SCHEMBL8378560 | 0.84 | GAA (0.49) | GAAABL1KDM4EALDH1A1MAPT | |
| SCHEMBL17118715 | 0.84 | MAPT (0.47) | GAAABL1NQO2ALDH1A1MAPT | |
| SCHEMBL19328721 | 0.84 | GAA (0.72) | GAAABL1NQO2KDM4EALDH1A1 | |
| SCHEMBL31487952 | 0.84 | MAPT (0.47) | GAAABL1NQO2ALDH1A1MAPT | |
| SCHEMBL7762378 | 0.84 | ABL1 (0.61) | GAAABL1NQO2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094953-A | 1, 3-Dihydro-2H-pyrrolo [3,4-c ] quinoline derivatives as cGAS inhibitors for the treatment of inflammatory and/or autoimmune diseases | — | 2026-05-26 | — | — | CN | disclosed |
| WO-2025040569-A1 | 1,3-DIHYDRO-2H-PYRROLO[3,4-C]QUINOLINE DERIVATIVES AS CGAS INHIBITORS FOR THE TREATMENT OF INFLAMMATORY AND/OR AUTOIMMUNE DISEASES | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-02-27 | — | — | WO | disclosed |
| US-10189843-B2 | Fused pyrazole derivative having autotaxin inhibitory activity | THE UNIVERSITY OF TOKYO (JP) | 2019-01-29 | — | — | US | disclosed |
| US-10150787-B2 | TC-PTP inhibitors as APC activators for immunotherapy | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2018-12-11 | — | — | US | disclosed |
| US-20180265531-A1 | TC-PTP INHIBITORS AS APC ACTIVATORS FOR IMMUNOTHERAPY | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2018-09-20 | — | — | US | disclosed |
| US-10005804-B2 | TC-PTP inhibitors as APC activators for immunotherapy | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIV (CA) | 2018-06-26 | — | — | US | disclosed |
| US-10005804-B2 | TC-PTP inhibitors as APC activators for immunotherapy | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIV (CA) | 2018-06-26 | — | — | US | disclosed |
| US-20180072763-A1 | TC-PTP INHIBITORS AS APC ACTIVATORS FOR IMMUNOTHERAPY | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIV (CA) | 2018-03-15 | — | — | US | disclosed |
| US-20180072763-A1 | TC-PTP INHIBITORS AS APC ACTIVATORS FOR IMMUNOTHERAPY | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIV (CA) | 2018-03-15 | — | — | US | disclosed |
| US-9828399-B2 | TC-PTP inhibitors as APC activators for immunotherapy | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2017-11-28 | — | — | US | disclosed |
| US-9828399-B2 | TC-PTP inhibitors as APC activators for immunotherapy | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2017-11-28 | — | — | US | disclosed |
| US-20170015690-A1 | TC-PTP INHIBITORS AS APC ACTIVATORS FOR IMMUNOTHERAPY | THE ROYAL INSTITUTE FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIVERSITY (CA) | 2017-01-19 | — | — | US | disclosed |
| US-20170015690-A1 | TC-PTP INHIBITORS AS APC ACTIVATORS FOR IMMUNOTHERAPY | THE ROYAL INSTITUTE FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIVERSITY (CA) | 2017-01-19 | — | — | US | disclosed |
| US-20170015690-A1 | TC-PTP INHIBITORS AS APC ACTIVATORS FOR IMMUNOTHERAPY | THE ROYAL INSTITUTE FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIVERSITY (CA) | 2017-01-19 | — | — | US | disclosed |
| EP-3110824-A1 | TC-PTP INHIBITORS AS APC ACTIVATORS FOR IMMUNOTHERAPY | The Royal Institution for the Advancement of Learning / McGill University (CA) | 2017-01-04 | — | — | EP | disclosed |
| US-20160376278-A1 | FUSED PYRAZOLE DERIVATIVE HAVING AUTOTAXIN INHIBITORY ACTIVITY | THE UNIVERSITY OF TOKYO (JP) | 2016-12-29 | — | — | US | disclosed |
| WO-2015127548-A1 | TC-PTP INHIBITORS AS APC ACTIVATORS FOR IMMUNOTHERAPY | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIVERSITY (CA) | 2015-09-03 | — | — | WO | disclosed |
| US-20070196270-A1 | Compounds As Ccri Antagonists | HENG RICHARD | 2007-08-23 | — | — | US | disclosed |
| US-20070196270-A1 | Compounds As Ccri Antagonists | HENG RICHARD | 2007-08-23 | — | — | US | disclosed |
| US-20070196270-A1 | Compounds As Ccri Antagonists | HENG RICHARD | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005804-B2 | TC-PTP inhibitors as APC activators for immunotherapy | PTPRCAP, PTPRC, PTPA | GAA 373/4885ABL1 422/4885NQO2 4277/4885 |
| US-10189843-B2 | Fused pyrazole derivative having autotaxin inhibitory activity | ENPP2, PRTN3, TPX2 | GAA 1152/4885ABL1 4664/4885NQO2 936/4885 |
| US-20170015690-A1 | TC-PTP INHIBITORS AS APC ACTIVATORS FOR IMMUNOTHERAPY | PTPRCAP, PTPRC, PTPA | GAA 373/4885ABL1 422/4885NQO2 4277/4885 |
| US-20180265531-A1 | TC-PTP INHIBITORS AS APC ACTIVATORS FOR IMMUNOTHERAPY | PTPRCAP, PTPRC, PTPA | GAA 373/4885ABL1 422/4885NQO2 4277/4885 |
| US-20160376278-A1 | FUSED PYRAZOLE DERIVATIVE HAVING AUTOTAXIN INHIBITORY ACTIVITY | ENPP2, PRTN3, TPX2 | GAA 1152/4885ABL1 4664/4885NQO2 936/4885 |
| US-20180072763-A1 | TC-PTP INHIBITORS AS APC ACTIVATORS FOR IMMUNOTHERAPY | PTPRCAP, PTPRC, PTPA | GAA 373/4885ABL1 422/4885NQO2 4277/4885 |
| US-10150787-B2 | TC-PTP inhibitors as APC activators for immunotherapy | PTPRCAP, PTPRC, PTPA | GAA 373/4885ABL1 422/4885NQO2 4277/4885 |
| US-20070196270-A1 | Compounds As Ccri Antagonists | CCR1, CCR10, CCR4 | GAA 2746/4885ABL1 2299/4885NQO2 2776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.